Affinage

ANGPT1

Angiopoietin-1 · UniProt Q15389

Round 2 corrected
Length
498 aa
Mass
57.5 kDa
Annotated
2026-04-28
130 papers in source corpus 27 papers cited in narrative 27 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

ANGPT1 is a secreted, multimeric glycoprotein ligand for the TIE2 receptor tyrosine kinase that serves as a central regulator of vascular stability, endothelial survival, and angiogenesis. Upon binding TIE2, ANGPT1 activates PI3K/AKT signaling at cell-cell contacts to promote endothelial survival and quiescence, or ERK signaling at cell-substratum contacts to drive migration, with integrin α5β1 sensitizing TIE2 to low ANGPT1 concentrations and recruiting FAK and PI3K to the receptor complex (PMID:18425120, PMID:16157706). ANGPT1 multimerization and N-glycosylation of its fibrinogen-like domain are required for full TIE2 binding and activation, and a loss-of-multimerization missense mutation (p.A119S) causes hereditary angioedema (PMID:28601681, PMID:26478188). Beyond blood vascular endothelium, ANGPT1/TIE2 signaling maintains satellite cell quiescence via ERK1/2, supports lymphatic vessel sprouting through VEGFR-3 upregulation, preserves alveolar epithelial barrier integrity by suppressing NF-κB, and its expression is transcriptionally controlled by repressor complexes (BRCA1/CtIP/ZBRK1; KDM3B/SMRT) and an activator (RXRα) as well as post-transcriptionally by miR-204 (PMID:19733541, PMID:15746084, PMID:20554518, PMID:16843262, PMID:25413303, PMID:39075504, PMID:27703260).

Mechanistic history

Synthesis pass · year-by-year structured walk · 16 steps
  1. 1996 High

    The identity of the TIE2 ligand was unknown; secretion-trap cloning identified ANGPT1 as the first ligand that binds and phosphorylates TIE2 without directly driving endothelial proliferation, establishing a new class of angiogenic factor, and concurrent knockout mice phenocopying Tie2-null embryos proved ANGPT1 is the essential physiologic TIE2 ligand required for endothelium–mesenchyme interactions during vascular development.

    Evidence Secretion-trap expression cloning with receptor binding/phosphorylation assays; targeted gene disruption in mice with embryonic phenotyping

    PMID:8980223 PMID:8980224

    Open questions at the time
    • Biochemical stoichiometry of ANGPT1–TIE2 interaction not determined
    • Signaling pathways downstream of TIE2 phosphorylation not yet mapped
  2. 1997 High

    The existence and identity of a natural ANGPT1 antagonist were unknown; identification of ANGPT2 as a competitive antagonist that disrupts vessel formation when overexpressed established the agonist–antagonist paradigm governing TIE2 signaling balance.

    Evidence Homology screening, receptor competition assay, transgenic ANGPT2 overexpression in mouse embryos

    PMID:9204896

    Open questions at the time
    • Whether ANGPT2 has any agonist activity in specific contexts was unresolved
    • Mechanism of context-dependent antagonism/agonism not defined
  3. 1998 High

    The functional outputs of ANGPT1 beyond vascular development were unclear; demonstration that ANGPT1 promotes capillary sprouting (synergizing with VEGF) and directed endothelial chemotaxis—both blocked by soluble TIE2 and antagonized by ANGPT2—defined ANGPT1 as a non-mitogenic pro-angiogenic and chemotactic factor acting exclusively through TIE2.

    Evidence 3D fibrin gel sprouting assay, chemotaxis assay with soluble TIE2/TIE1 controls and ANGPT2 competition

    PMID:9560344 PMID:9660821

    Open questions at the time
    • Intracellular signaling pathways mediating sprouting and chemotaxis not delineated
    • Role of co-receptors or integrins not yet explored
  4. 1999 High

    Whether ANGPT1 directly regulated endothelial survival was untested; dose-dependent inhibition of apoptosis in serum-deprived HUVECs, synergizing with VEGF, established ANGPT1 as a bona fide endothelial survival factor.

    Evidence Apoptosis assay with dose-response in primary HUVECs

    PMID:10218485

    Open questions at the time
    • Downstream survival pathway (AKT vs. other) not yet demonstrated
    • In vivo anti-apoptotic role not shown
  5. 2004 High

    The signaling pathway mediating ANGPT1-driven survival and the structural basis for ANGPT1 potency were open questions; AKT was identified as the essential downstream mediator of both survival and sprouting via dominant-negative/constitutively-active epistasis, while engineering of COMP-Ang1 revealed that a defined oligomerization domain could replace the native aggregation domain to produce a super-potent, soluble TIE2 agonist that protects against radiation-induced endothelial apoptosis in vivo.

    Evidence Dominant-negative/constitutively-active AKT constructs; COMP-Ang1 protein engineering with in vitro/in vivo TIE2 and AKT phosphorylation, radiation injury model

    PMID:15060279 PMID:15060280 PMID:15242771

    Open questions at the time
    • Whether ERK contributes to ANGPT1 responses in certain contexts was unknown
    • Structural details of ANGPT1 multimerization at atomic level not resolved
  6. 2005 High

    How TIE2 integrates signals with the extracellular matrix was uncharacterized; α5β1 integrin was shown to constitutively associate with TIE2, sensitize it to low ANGPT1 concentrations, and recruit PI3K (p85) and FAK to the complex, with α5β1 blockade abolishing Ang1-dependent angiogenesis in vivo—establishing integrin co-signaling as essential for ANGPT1 function.

    Evidence Reciprocal co-IP, blocking antibodies against α5β1/αvβ3, FAK phosphorylation assay, in vivo angiogenesis

    PMID:16157706

    Open questions at the time
    • Whether other integrins contribute in different vascular beds was not tested
    • Crystal structure of TIE2–integrin complex not available
  7. 2005 High

    ANGPT1 function in the lymphatic vasculature was unexplored; demonstration that ANGPT1/TIE2 signaling promotes lymphatic endothelial proliferation and sprouting through upregulation of VEGFR-3 expanded the biological scope of ANGPT1 beyond blood vasculature.

    Evidence Viral and transgenic ANGPT1 overexpression in mice, lymphatic endothelial cell assays, soluble VEGFR-3 inhibition

    PMID:15746084

    Open questions at the time
    • Whether ANGPT1 is required for lymphatic development physiologically (loss-of-function) was not tested
    • Downstream signaling in lymphatic vs. blood endothelium not compared
  8. 2006 High

    Transcriptional regulation of ANGPT1 was undefined; identification of the BRCA1/CtIP/ZBRK1 repressor complex occupying the ANGPT1 promoter, with BRCA1 loss leading to ANGPT1 overexpression and tumor hypervascularization, linked ANGPT1 transcriptional control to tumor suppressor pathways.

    Evidence ChIP, promoter reporter assay, Brca1-deficient mouse mammary tumor analysis

    PMID:16843262

    Open questions at the time
    • Whether this repressor complex operates in non-tumor contexts was not tested
    • Other transcriptional regulators of ANGPT1 not yet identified
  9. 2008 High

    How a single ligand–receptor pair produces divergent downstream outcomes was unexplained; spatial dissection showed that ANGPT1 bridges TIE2 in trans at cell-cell junctions (preferentially activating AKT for quiescence) versus localizing TIE2 at cell-ECM contacts (preferentially activating ERK for migration), providing a molecular framework for context-dependent ANGPT1 signaling.

    Evidence Live-cell imaging, immunoprecipitation, kinase assays, ECM-tethered Ang1, microarray with qPCR validation

    PMID:18425120

    Open questions at the time
    • In vivo validation of the spatial signaling model in intact vessels not provided
    • Whether ANGPT2 also exhibits spatial biased signaling was not addressed
  10. 2009 High

    The context dependency of ANGPT2 activity and ANGPT1 function outside endothelium were unresolved; ANGPT2 was shown to act as a partial agonist of TIE2 in the absence of ANGPT1 but a competitive antagonist in its presence, resolving conflicting reports, while ANGPT1/TIE2/ERK1/2 signaling was discovered to maintain skeletal muscle satellite cell quiescence—the first demonstration of ANGPT1 function in a non-endothelial stem cell niche.

    Evidence TIE2 phosphorylation and AKT assays with varying ANGPT1/2 ratios and siRNA; satellite cell flow cytometry, BrdU labeling, Tie2 siRNA, in vivo Ang1 overexpression

    PMID:19223473 PMID:19733541

    Open questions at the time
    • Structural basis for partial agonism of ANGPT2 unknown
    • Whether other quiescent stem cell niches use ANGPT1/TIE2 not explored
  11. 2010 High

    ANGPT1 functions beyond endothelial cells were emerging but incompletely understood; ANGPT1 was shown to protect alveolar epithelial barrier integrity by suppressing NF-κB–driven actin stress fiber formation and claudin-18 disorganization, while in endothelium the TIE2–ILK–mTOR–HIF-1α–SDF-1 axis was delineated as a mechanism for progenitor cell recruitment under ischemia.

    Evidence siRNA knockdown of ANGPT1 in MSC co-culture with epithelial permeability readout; Co-IP of TIE2–ILK, siRNA against HIF-1α, in vivo ischemia model

    PMID:20554518 PMID:21200018

    Open questions at the time
    • Whether epithelial protection occurs via a TIE2-independent receptor was not ruled out
    • ILK–mTOR axis not validated with genetic ILK loss-of-function
  12. 2013 Medium

    How hypoxia suppresses ANGPT1/TIE2 signaling despite maintained ligand availability was unexplained; TIE1 was identified as a negative regulator whose hypoxia-induced upregulation attenuates ANGPT1-induced TIE2 phosphorylation independently of phosphatase activity, with TIE1 silencing fully restoring TIE2 activation.

    Evidence TIE2 phosphorylation assay, TIE1 siRNA epistasis, ANGPT1 binding assay under hypoxia

    PMID:23770419

    Open questions at the time
    • Mechanism by which TIE1 inhibits TIE2 (steric, conformational) not defined
    • In vivo validation of TIE1-dependent suppression under hypoxia not performed
  13. 2015 Medium

    Additional layers of ANGPT1 transcriptional control and the structural requirements for receptor activation needed characterization; a second repressor complex (KDM3B/SMRT), acting independently of demethylase catalytic activity, was found at the ANGPT1 promoter, and N-glycosylation within the fibrinogen-like domain was shown to be required for TIE2 activation, migration, and vascular stabilization.

    Evidence ChIP and co-IP for KDM3B/SMRT, JmjC catalytic mutant; N-glycosylation site mutagenesis with functional assays and in vivo vascular leakage

    PMID:25413303 PMID:26478188

    Open questions at the time
    • Relationship between KDM3B/SMRT and BRCA1/CtIP/ZBRK1 repressor complexes not explored
    • Which specific glycan structures are required for TIE2 binding unknown
  14. 2017 High

    Whether ANGPT1 mutations cause human disease was unknown; identification of p.A119S in hereditary angioedema families, with demonstration that the mutant protein fails to multimerize and shows reduced TIE2 binding, provided the first direct human genetic link and proved that multimerization is essential for receptor engagement.

    Evidence Whole-exome sequencing of familial cohort, recombinant mutant protein analysis, TIE2 binding and multimer assays

    PMID:28601681

    Open questions at the time
    • Crystal structure of mutant vs. wild-type multimer not available
    • Mechanism linking reduced TIE2 signaling to angioedema pathophysiology not fully elucidated
  15. 2023 Medium

    How ANGPT1 coordinates with junctional and phosphatase-level regulation to stabilize vessels remained incomplete; Ang1/Tie2 signaling was shown to upregulate VE-cadherin and downregulate VEGFR2 at endothelial junctions, with VE-PTP inhibition phenocopying Ang1 effects on vessel perfusion in vivo.

    Evidence 3D spheroid sprouting assay, SCID mouse in vivo vascularization with VE-PTP inhibitor, Western blot

    PMID:38058134

    Open questions at the time
    • Whether VE-PTP inhibition acts solely through TIE2 or also other substrates was not dissected
    • Long-term vessel stability not assessed
  16. 2024 Medium

    Transcriptional activators of ANGPT1 in pericytes were unidentified; CCL28-driven retinoic acid metabolism was shown to increase ANGPT1 expression through direct RXRα binding to the ANGPT1 promoter, establishing a paracrine mechanism by which pericyte-derived ANGPT1 promotes vessel stabilization after anti-angiogenesis therapy.

    Evidence ChIP-qPCR for RXRα at ANGPT1 promoter, RNA-seq, LC-MS metabolomics, single-cell sequencing

    PMID:39075504

    Open questions at the time
    • Whether RXRα cooperates with other nuclear receptors at the ANGPT1 promoter unknown
    • Functional consequence of blocking RXRα on ANGPT1-dependent vessel stabilization not tested in vivo

Open questions

Synthesis pass · forward-looking unresolved questions
  • A high-resolution structural model of the full-length ANGPT1 multimer bound to TIE2 is lacking, the precise mechanism by which TIE1 inhibits TIE2 signaling under hypoxia is unresolved, and whether ANGPT1/TIE2 signaling maintains quiescence in stem cell niches beyond satellite cells remains to be determined.
  • No atomic-resolution structure of ANGPT1 multimer–TIE2 complex
  • Mechanism of TIE1-mediated TIE2 suppression undefined at molecular level
  • ANGPT1 roles in non-vascular, non-satellite cell stem cell niches untested

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0048018 receptor ligand activity 5 GO:0098631 cell adhesion mediator activity 1
Localization
GO:0005576 extracellular region 4 GO:0031012 extracellular matrix 1
Pathway
R-HSA-162582 Signal Transduction 5 R-HSA-5357801 Programmed Cell Death 3 R-HSA-1266738 Developmental Biology 2 R-HSA-1500931 Cell-Cell communication 2 GO:0048018 receptor ligand activity 1
Partners
ANGPT2ILKITGA5ITGB1TEKVE-PTP

Evidence

Reading pass · 27 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1996 Angiopoietin-1 (ANGPT1) was identified as a secreted ligand for the TIE2 receptor tyrosine kinase using secretion-trap expression cloning. ANGPT1 binds and induces tyrosine phosphorylation of TIE2 but does not directly promote proliferation of cultured endothelial cells, implicating it in endothelial developmental processes distinct from classical mitogenic growth factors. Secretion-trap expression cloning in COS cells, receptor binding assay, tyrosine phosphorylation assay Cell High 8980223
1996 Genetic knockout of Angiopoietin-1 in mice produces angiogenic deficits identical to those seen in Tie2-null mice, demonstrating that ANGPT1 is the primary physiologic ligand for TIE2 in vivo and plays a critical role mediating reciprocal interactions between the endothelium and surrounding matrix/mesenchyme during embryonic vascular development. Targeted gene disruption (knockout mouse), embryonic phenotype analysis Cell High 8980224
1997 Angiopoietin-2 (ANGPT2) was identified as a naturally occurring antagonist of ANGPT1 at the TIE2 receptor; transgenic overexpression of ANGPT2 disrupts blood vessel formation in the mouse embryo in a manner opposite to ANGPT1, and in adults ANGPT2 is expressed only at sites of vascular remodeling. Homology screening, transgenic overexpression, receptor competition assay Science High 9204896
1998 ANGPT1 induces capillary sprouting from endothelial cell monolayers in a three-dimensional fibrin gel assay in a dose-dependent manner, acting only weakly as a mitogen but synergizing with VEGF at suboptimal concentrations; sprouting is completely inhibited by soluble TIE2 extracellular domain, confirming TIE2 as the mediating receptor. 3D fibrin gel sprouting assay, soluble receptor inhibition, dose-response Current Biology High 9560344
1998 ANGPT1, but not ANGPT2, is chemotactic for endothelial cells via TIE2; excess soluble TIE2 (but not TIE1) abolishes the chemotactic response, and ANGPT2 dose-dependently blocks Ang1-directed migration, acting as a competitive antagonist. Fibroblasts stably transfected with TIE2 also exhibit chemotaxis toward both angiopoietins. Chemotaxis assay, soluble receptor competition, stable TIE2 transfection in fibroblasts The Journal of Biological Chemistry High 9660821
1999 ANGPT1 functions as an apoptosis survival factor for endothelial cells: it dose-dependently inhibits apoptosis in serum-deprived HUVECs, with synergistic anti-apoptotic effects when combined with VEGF. Apoptosis assay (dose-response) in serum-deprived HUVECs FEBS Letters High 10218485
2004 Replacement of the N-terminal aggregation domain of native ANGPT1 with the short coiled-coil domain of cartilage oligomeric matrix protein (COMP) yields COMP-Ang1, a soluble, stable, and potent variant that is more potent than native ANGPT1 in phosphorylating the TIE2 receptor and AKT in primary endothelial cells, and enhances angiogenesis in vitro and in vivo. Protein engineering, TIE2/AKT phosphorylation assay, in vitro angiogenesis, in vivo mouse angiogenesis model Proceedings of the National Academy of Sciences High 15060279
2004 COMP-Ang1 administered intravenously is more potent than native ANGPT1 in phosphorylating TIE2 in lung endothelial cells in vivo and localizes preferentially to microvascular endothelial cells of the intestinal villi and lung, protecting against radiation-induced apoptosis in these compartments. In vivo TIE2 phosphorylation, immunolocalization, radiation injury model in mice Proceedings of the National Academy of Sciences High 15060280
2004 AKT is the primary mediator of ANGPT1/TIE2-induced endothelial cell survival: blocking AKT abolishes Ang1-mediated EC survival, while activating AKT rescues TIE2 blockade-induced apoptosis. AKT is also required for both Ang1- and VEGF-induced EC sprouting in 3D collagen gels. Dominant-negative/constitutively active AKT constructs, 3D sprouting assay, receptor blockade Experimental Cell Research High 15242771
2005 Alpha5beta1 integrin constitutively interacts with TIE2 and specifically sensitizes TIE2 to low concentrations of ANGPT1, allowing endothelial cell survival and inducing persistent motility. Fibronectin binding to alpha5beta1 increases this association, and ANGPT1 stimulation recruits p85 (PI3K regulatory subunit) and FAK to the TIE2/alpha5beta1 complex. ANGPT1 selectively mediates alpha5beta1 outside-in FAK phosphorylation. Blocking alpha5beta1 (but not alphavbeta3) abolishes Ang1-dependent angiogenesis in vivo. Co-immunoprecipitation, blocking antibodies, FAK phosphorylation assay, in vivo angiogenesis model The Journal of Cell Biology High 16157706
2005 ANGPT1 promotes lymphatic endothelial proliferation, vessel enlargement, and sprouting via TIE2 expressed on lymphatic endothelial cells; Ang1 stimulation of lymphatic endothelial cells upregulates VEGFR-3, and soluble VEGFR-3 inhibits Ang1-induced lymphatic sprouting. Viral vector overexpression in mice, transgenic mice, lymphatic endothelial cell assays, soluble receptor inhibition Blood High 15746084
2006 BRCA1, CtIP, and ZBRK1 form a transcriptional repressor complex that coordinately represses ANGPT1 expression via a ZBRK1 recognition site in the ANGPT1 promoter. Impairment of this complex upregulates ANGPT1, which stabilizes endothelial cells forming capillary-like networks. Brca1-deficient mouse mammary tumors exhibit overexpressed ANGPT1 and pronounced vascularization. ChIP, promoter reporter assay, microarray, 3D cell culture, mouse tumor model Cancer Cell High 16843262
2008 ANGPT1 activates TIE2 differentially depending on cellular context: at cell-cell contacts, Ang1 bridges TIE2 in trans-association, leading to preferential AKT activation; at cell-substratum contacts, ECM-bound Ang1 localizes TIE2 to cell-substratum contacts, leading to preferential ERK activation. These distinct spatial localizations produce different gene expression profiles in endothelial cells. Live cell imaging, immunoprecipitation, kinase assays, microarray with real-time PCR validation, Ang1 tethering to ECM Nature Cell Biology High 18425120
2008 Hepatic stellate cells (HSCs) are the primary source of ANGPT1 in fibrotic liver; activated HSCs express and secrete ANGPT1 more abundantly than quiescent HSCs, and TNF-alpha stimulates ANGPT1 expression in an NF-kB-dependent manner. Blocking angiopoietin signaling via adenoviral soluble TIE2 (AdsTie2) inhibits angiogenesis and liver fibrosis in CCl4 and bile duct ligation models. HSC isolation and culture, adenoviral soluble receptor blockade, NF-kB inhibition, in vivo fibrosis models Gastroenterology High 18823985
2009 ANGPT2 functions as a partial agonist/antagonist of TIE2 depending on context: in the absence of ANGPT1, ANGPT2 activates TIE2 and the PI3K/AKT pathway supporting EC survival, migration, and tube formation, but when ANGPT1 is present, ANGPT2 dose-dependently inhibits ANGPT1-induced TIE2 phosphorylation and AKT activation. Endogenous ANGPT2 (from ECs) maintains basal TIE2/AKT activity. TIE2 phosphorylation assay, AKT activation assay, EC survival/migration/tube formation, siRNA knockdown of endogenous ANGPT2 Molecular and Cellular Biology High 19223473
2009 Ang1/Tie2/PI3K signaling axis initiates survival responses in neural progenitor cells (NPCs) against oxygen-glucose deprivation (OGD): Ang1 prevents OGD-induced apoptosis via TIE2 autophosphorylation and PI3K activation, reversing Akt dephosphorylation, Bcl-2/Bax ratio decrease, caspase-3 activation, and PARP cleavage. Blocking TIE2 (with sTie2Fc) or PI3K (LY294002) abrogates Ang1 protection. TUNEL, annexin V labeling, TIE2 phosphorylation, PI3K inhibition, soluble receptor blockade in OGD model Neuroscience Medium 19409199
2009 Muscle satellite cells (quiescent state) express TIE2, while proliferating myogenic precursors do not. Ang1/Tie2 signaling through the ERK1/2 pathway decreases proliferation and differentiation of myogenic precursor cells and promotes return to G0/quiescence. Silencing Tie2 has opposite effects. In vivo, Tie2 blockade increases cycling satellite cells while Ang1 overexpression increases quiescent satellite cells. Flow cytometry, BrdU labeling, siRNA knockdown, ERK1/2 pathway analysis, in vivo Ang1 overexpression and Tie2 blockade Cell Stem Cell High 19733541
2010 COMP-Ang1 stimulates HIF-1alpha-mediated SDF-1 overexpression in hypoxic endothelium through mTOR activation. Mechanistically, COMP-Ang1/TIE2 signaling enhances binding of TIE2 to integrin-linked kinase (ILK), which acts as an upstream activator of mTOR, thereby linking ANGPT1-TIE2 to the mTOR/HIF-1alpha/SDF-1 axis driving bone marrow progenitor cell recruitment. siRNA against HIF-1alpha, mTOR pathway analysis, Co-IP of TIE2 and ILK, SDF-1 ELISA, in vivo ischemia model Blood High 21200018
2010 MSCs overexpressing ANGPT1 restore alveolar epithelial permeability to protein after cytokine-induced injury by preventing actin stress fiber formation and claudin-18 disorganization through suppression of NF-kB activity. siRNA knockdown of ANGPT1 secretion from MSCs abolishes this protective effect on epithelial barrier function. siRNA knockdown, albumin flux assay (permeability), actin/claudin immunostaining, NF-kB reporter, co-culture The Journal of Biological Chemistry High 20554518
2013 Hypoxia reduces endothelial Ang1-induced Tie2 activity in a Tie1-dependent manner: hypoxia increases TIE1 expression but attenuates ANGPT1-induced TIE2 phosphorylation, downstream signaling, and tube formation, even though ANGPT1 binding to endothelial cells is increased. TIE1 suppression restores TIE2 activity, and the suppression is independent of tyrosine phosphatase activity. TIE2 phosphorylation assay, TIE1 siRNA knockdown, tube formation assay, ANGPT1 binding assay under hypoxia Biochemical and Biophysical Research Communications Medium 23770419
2015 Transcription of ANGPT1 is repressed by the histone H3K9 demethylase KDM3B via interaction with the corepressor SMRT; this repression is independent of KDM3B's JmjC-domain catalytic demethylase activity. The KDM3B-SMRT repressor complex is recruited to the ANGPT1 promoter. Depletion of KDM3B increases cell proliferation and motility, implicating ANGPT1 regulation in angiogenesis. ChIP, co-IP (KDM3B-SMRT interaction), JmjC catalytic mutant analysis, MTT proliferation assay, wound healing assay BMB Reports Medium 25413303
2015 Dimeric CMP-Ang1, an engineered ANGPT1 variant, activates TIE2 and stimulates angiogenesis and vascular stabilization in an N-glycosylation-dependent manner; specific N-glycosylation in the fibrinogen-like domain of ANGPT1 is required for its TIE2-activating effects on endothelial cell migration, survival, and tube formation. N-glycosylation mutants, TIE2 phosphorylation assay, endothelial cell functional assays, in vivo vascular leakage assay Scientific Reports Medium 26478188
2016 miR-204 directly targets ANGPT1 (and TGFBR2) in breast cancer: luciferase reporter and rescue assays confirm ANGPT1 is a direct downstream effector of miR-204. Knockdown of ANGPT1 (but not alone of TGFBR2) inhibits 3D capillary network formation, implicating ANGPT1 specifically in tumor angiogenesis downstream of miR-204. Luciferase reporter assay, rescue assay, gain-of-function miRNA transfection, siRNA knockdown, in vitro angiogenesis Scientific Reports Medium 27703260
2017 A missense mutation in ANGPT1 (p.A119S) causes hereditary angioedema in a familial cohort. The mutant protein forms reduced amounts of multimers and shows reduced binding capability to TIE2 receptor, demonstrating that ANGPT1 multimerization is required for normal receptor binding and vascular function. Whole-exome sequencing, protein analysis of patient plasma, recombinant protein expression, TIE2 binding assay, multimer analysis The Journal of Allergy and Clinical Immunology High 28601681
2018 ANGPT1 negatively regulates NF-kB (p65) phosphorylation in endothelial cells: overexpression of Ang1 decreases phospho-p65, and this suppression of NF-kB is a mechanism by which Ang1 protects against LPS/macrophage-induced endothelial cell apoptosis and dysfunction. Plasmid transfection/overexpression, siRNA, Western blot for p-p65, cell viability and apoptosis assays Scientific Reports Medium 33536546
2023 In vascular stabilization by dental pulp stem cell-derived pericyte-like cells, the Ang1/Tie2/VE-cadherin signaling axis is critical: Ang1 treatment or VE-PTP inhibitor pretreatment increases blood vessel perfusion in vivo. Ang1 activates Tie2 signaling to upregulate VE-cadherin and downregulate VEGFR2, stabilizing endothelial junctions and suppressing sprouting. 3D spheroid sprouting assay, SCID mouse in vivo vascularization, VE-PTP inhibitor, Western blot, immunostaining Journal of Dental Research Medium 38058134
2024 CCL28 recruits pericytes to tumors after anti-angiogenesis therapy, and within these pericytes, CCL28 modifies retinoic acid (RA) metabolism and increases ANGPT1 expression via RXRα. ChIP-qPCR demonstrates direct transcriptional regulatory binding of RXRα to the ANGPT1 promoter, establishing RA/RXRα as a transcriptional activator of ANGPT1 in pericytes that promotes endothelial stabilization. ChIP-qPCR, RNA sequencing, western blot, LC-MS metabolomics, single-cell sequencing, immunofluorescence Journal of Experimental and Clinical Cancer Research Medium 39075504

Source papers

Stage 0 corpus · 130 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1997 Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science (New York, N.Y.) 2888 9204896
1996 Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 2296 8980224
1996 Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1601 8980223
2002 Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proceedings of the National Academy of Sciences of the United States of America 1479 12477932
2021 Dual proteome-scale networks reveal cell-specific remodeling of the human interactome. Cell 705 33961781
2011 Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Briefings in bioinformatics 656 21873635
2007 Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. PLoS medicine 497 17803352
2022 OpenCell: Endogenous tagging for the cartography of human cellular organization. Science (New York, N.Y.) 432 35271311
1997 Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene 389 9188862
1998 Angiopoietin-1 induces sprouting angiogenesis in vitro. Current biology : CB 384 9560344
1999 Angiopoietins 3 and 4: diverging gene counterparts in mice and humans. Proceedings of the National Academy of Sciences of the United States of America 378 10051567
1998 Chemotactic properties of angiopoietin-1 and -2, ligands for the endothelial-specific receptor tyrosine kinase Tie2. The Journal of biological chemistry 375 9660821
2004 Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer cell 369 15542434
2009 Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Molecular and cellular biology 322 19223473
1998 Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C. The Journal of biological chemistry 322 9525952
2008 Differential function of Tie2 at cell-cell contacts and cell-substratum contacts regulated by angiopoietin-1. Nature cell biology 310 18425120
2013 Loci associated with N-glycosylation of human immunoglobulin G show pleiotropy with autoimmune diseases and haematological cancers. PLoS genetics 292 23382691
2003 Hypoxia-inducible factor-1 mediates activation of cultured vascular endothelial cells by inducing multiple angiogenic factors. Circulation research 271 12958144
2000 Structural basis for the anticoagulant activity of the thrombin-thrombomodulin complex. Nature 270 10761923
2009 Proteomic analysis of human parotid gland exosomes by multidimensional protein identification technology (MudPIT). Journal of proteome research 237 19199708
2008 Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis. Gastroenterology 226 18823985
2004 COMP-Ang1: a designed angiopoietin-1 variant with nonleaky angiogenic activity. Proceedings of the National Academy of Sciences of the United States of America 219 15060279
2010 Allogeneic human mesenchymal stem cells restore epithelial protein permeability in cultured human alveolar type II cells by secretion of angiopoietin-1. The Journal of biological chemistry 214 20554518
2017 Mutation of the angiopoietin-1 gene (ANGPT1) associates with a new type of hereditary angioedema. The Journal of allergy and clinical immunology 213 28601681
2009 A genome-wide short hairpin RNA screening of jurkat T-cells for human proteins contributing to productive HIV-1 replication. The Journal of biological chemistry 211 19460752
1999 Angiopoietin-1 is an apoptosis survival factor for endothelial cells. FEBS letters 208 10218485
1994 Prediction of the coding sequences of unidentified human genes. I. The coding sequences of 40 new genes (KIAA0001-KIAA0040) deduced by analysis of randomly sampled cDNA clones from human immature myeloid cell line KG-1. DNA research : an international journal for rapid publication of reports on genes and genomes 207 7584026
2005 Angiopoietin-1 promotes lymphatic sprouting and hyperplasia. Blood 193 15746084
2002 Human placental vascular development: vasculogenic and angiogenic (branching and nonbranching) transformation is regulated by vascular endothelial growth factor-A, angiopoietin-1, and angiopoietin-2. The Journal of clinical endocrinology and metabolism 191 12213874
2007 Therapeutic benefits by human mesenchymal stem cells (hMSCs) and Ang-1 gene-modified hMSCs after cerebral ischemia. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 185 17637706
2009 Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. The American journal of pathology 181 19815705
2009 Autocrine and paracrine angiopoietin 1/Tie-2 signaling promotes muscle satellite cell self-renewal. Cell stem cell 175 19733541
2007 Proangiogenic cytokines as hypoxia-dependent factors stimulating migration of human hepatic stellate cells. The American journal of pathology 172 17525262
2009 Serum angiopoietin-1 and -2 levels discriminate cerebral malaria from uncomplicated malaria and predict clinical outcome in African children. PloS one 171 19300530
2005 Stable interaction between alpha5beta1 integrin and Tie2 tyrosine kinase receptor regulates endothelial cell response to Ang-1. The Journal of cell biology 150 16157706
2017 Mesenchymal Stem Cell Microvesicles Attenuate Acute Lung Injury in Mice Partly Mediated by Ang-1 mRNA. Stem cells (Dayton, Ohio) 143 28376568
2004 Designed angiopoietin-1 variant, COMP-Ang1, protects against radiation-induced endothelial cell apoptosis. Proceedings of the National Academy of Sciences of the United States of America 119 15060280
2021 Exosomal lncRNA-H19 promotes osteogenesis and angiogenesis through mediating Angpt1/Tie2-NO signaling in CBS-heterozygous mice. Theranostics 116 34335960
2005 Long-term and sustained COMP-Ang1 induces long-lasting vascular enlargement and enhanced blood flow. Circulation research 111 15961719
2006 Localization of Ang-1, -2, Tie-2, and VEGF expression at endothelial-pericyte interdigitation in rat angiogenesis. Laboratory investigation; a journal of technical methods and pathology 110 16969369
2004 Akt is a major angiogenic mediator downstream of the Ang1/Tie2 signaling pathway. Experimental cell research 103 15242771
2006 Removal of BRCA1/CtIP/ZBRK1 repressor complex on ANG1 promoter leads to accelerated mammary tumor growth contributed by prominent vasculature. Cancer cell 87 16843262
2011 COMP-Ang1 stimulates HIF-1α-mediated SDF-1 overexpression and recovers ischemic injury through BM-derived progenitor cell recruitment. Blood 72 21200018
2010 Hedgehog promotes neovascularization in pancreatic cancers by regulating Ang-1 and IGF-1 expression in bone-marrow derived pro-angiogenic cells. PloS one 72 20098680
2008 Ang-1 gene therapy inhibits hypoxia-inducible factor-1alpha (HIF-1alpha)-prolyl-4-hydroxylase-2, stabilizes HIF-1alpha expression, and normalizes immature vasculature in db/db mice. Diabetes 66 18835934
2000 Early effects of hypoxia/reoxygenation on VEGF, ang-1, ang-2 and their receptors in the rat myocardium: implications for myocardial angiogenesis. Molecular and cellular biochemistry 66 11129953
2016 Dual targeting of ANGPT1 and TGFBR2 genes by miR-204 controls angiogenesis in breast cancer. Scientific reports 63 27703260
2019 Tsantan Sumtang attenuated chronic hypoxia-induced right ventricular structure remodeling and fibrosis by equilibrating local ACE-AngII-AT1R/ACE2-Ang1-7-Mas axis in rat. Journal of ethnopharmacology 60 31862407
2012 The attenuation of restenosis following arterial gene transfer using carbon nanotube coated stent incorporating TAT/DNA(Ang1+Vegf) nanoparticles. Biomaterials 55 22818986
2009 COMP-Ang1, a chimeric form of Angiopoietin 1, enhances BMP2-induced osteoblast differentiation and bone formation. Bone 55 19782780
2015 Intravitreal AAV2.COMP-Ang1 Prevents Neurovascular Degeneration in a Murine Model of Diabetic Retinopathy. Diabetes 53 26340930
2008 Increasing Ang1/Tie2 expression by simvastatin treatment induces vascular stabilization and neuroblast migration after stroke. Journal of cellular and molecular medicine 53 18544044
2018 Bee venom improves diabetic wound healing by protecting functional macrophages from apoptosis and enhancing Nrf2, Ang-1 and Tie-2 signaling. Molecular immunology 52 30366166
2000 Placental defects in ARNT-knockout conceptus correlate with localized decreases in VEGF-R2, Ang-1, and Tie-2. Developmental dynamics : an official publication of the American Association of Anatomists 50 11084652
2011 A nanobiohybrid complex of recombinant baculovirus and Tat/DNA nanoparticles for delivery of Ang-1 transgene in myocardial infarction therapy. Biomaterials 48 21840594
2020 Blocking exosomal miRNA-153-3p derived from bone marrow mesenchymal stem cells ameliorates hypoxia-induced myocardial and microvascular damage by targeting the ANGPT1-mediated VEGF/PI3k/Akt/eNOS pathway. Cellular signalling 47 33164880
2009 Nitric oxide donor up-regulation of SDF1/CXCR4 and Ang1/Tie2 promotes neuroblast cell migration after stroke. Journal of neuroscience research 43 18711749
2010 Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release. Expert opinion on investigational drugs 40 20050812
2007 Conditional activation of FGFR1 in the prostate epithelium induces angiogenesis with concomitant differential regulation of Ang-1 and Ang-2. Oncogene 40 17297442
2023 A Triple-Targeted Rutin-Based Self-Assembled Delivery Vector for Treating Ischemic Stroke by Vascular Normalization and Anti-Inflammation via ACE2/Ang1-7 Signaling. ACS central science 38 37396868
2017 ACE-2/Ang1-7/Mas cascade mediates ACE inhibitor, captopril, protective effects in estrogen-deficient osteoporotic rats. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 37 28531801
2012 Grape seed proanthocyanidins inhibit colon cancer-induced angiogenesis through suppressing the expression of VEGF and Ang1. International journal of molecular medicine 34 23026853
2008 Angiopoietin-1 variant, COMP-Ang1 attenuates hydrogen peroxide-induced acute lung injury. Experimental & molecular medicine 33 18587270
2021 Exosomal miR-3682-3p Suppresses Angiogenesis by Targeting ANGPT1 via the RAS-MEK1/2-ERK1/2 Pathway in Hepatocellular Carcinoma. Frontiers in cell and developmental biology 31 33869178
2021 l-Borneol Exerted the Neuroprotective Effect by Promoting Angiogenesis Coupled With Neurogenesis via Ang1-VEGF-BDNF Pathway. Frontiers in pharmacology 30 33746762
2017 The ACE-2/Ang1-7/Mas cascade enhances bone structure and metabolism following angiotensin-II type 1 receptor blockade. European journal of pharmacology 30 28442323
2015 Cornin increases angiogenesis and improves functional recovery after stroke via the Ang1/Tie2 axis and the Wnt/β-catenin pathway. Archives of pharmacal research 30 26276673
2011 Radiation attenuates physiological angiogenesis by differential expression of VEGF, Ang-1, tie-2 and Ang-2 in rat brain. Radiation research 30 21962003
2007 Angiopoietin 1 (Ang-1), angiopoietin 2 (Ang-2) and Tie-2 (a receptor tyrosine kinase) concentrations in peripheral blood of patients with thyroid cancers. Cytokine 30 17374490
2018 ACE-2/ANG1-7 ameliorates ER stress-induced apoptosis in seawater aspiration-induced acute lung injury. American journal of physiology. Lung cellular and molecular physiology 29 30335496
2010 Protective role of COMP-Ang1 in ischemic rat brain. Journal of neuroscience research 28 19885826
2009 COMP-Ang1 ameliorates leukocyte adhesion and reinforces endothelial tight junctions during endotoxemia. Biochemical and biophysical research communications 28 19245790
2009 An Ang1-Tie2-PI3K axis in neural progenitor cells initiates survival responses against oxygen and glucose deprivation. Neuroscience 28 19409199
2024 Ang-1 and VEGF: central regulators of angiogenesis. Molecular and cellular biochemistry 27 38652215
2014 Placental mRNA expression of angiopoietins (Ang)-1, Ang-2 and their receptor Tie-2 is altered in pregnancies complicated by preeclampsia. Placenta 27 25047691
2016 Expression of angiogenic growth factors VEGF, bFGF and ANG1 in colon cancer after bevacizumab treatment in vitro: A potential self-regulating mechanism. Oncology reports 26 27840995
2015 A Designed Angiopoietin-1 Variant, Dimeric CMP-Ang1 Activates Tie2 and Stimulates Angiogenesis and Vascular Stabilization in N-glycan Dependent Manner. Scientific reports 24 26478188
2015 Puerarin accelerate scardiac angiogenesis and improves cardiac function of myocardial infarction by upregulating VEGFA, Ang-1 and Ang-2 in rats. International journal of clinical and experimental medicine 24 26885006
2004 Role of Ang1 and its interaction with VEGF-A in astrocytomas. Journal of neuropathology and experimental neurology 24 15453096
2018 Integrin α5β1-Ang1/Tie2 receptor cross-talk regulates brain endothelial cell responses following cerebral ischemia. Experimental & molecular medicine 23 30185785
2015 Improving the efficacy of therapeutic angiogenesis by UTMD-mediated Ang-1 gene delivery to the infarcted myocardium. International journal of molecular medicine 23 26035181
2018 GM-CSF ameliorates microvascular barrier integrity via pericyte-derived Ang-1 in wound healing. Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society 22 29328541
2017 Ang1/Tie2 induces cell proliferation and migration in human papillary thyroid carcinoma via the PI3K/AKT pathway. Oncology letters 21 29387247
2011 Unique angiogenic and vasculogenic properties of renal cell carcinoma in a xenograft model of bone metastasis are associated with high levels of vegf-a and decreased ang-1 expression. Journal of orthopaedic research : official publication of the Orthopaedic Research Society 21 21809376
2023 Cold atmospheric plasma induces the curing mechanism of diabetic wounds by regulating the oxidative stress mediators iNOS and NO, the pyroptotic mediators NLRP-3, Caspase-1 and IL-1β and the angiogenesis mediators VEGF and Ang-1. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 19 38000357
2021 Transplantation of 3D bio-printed cardiac mesh improves cardiac function and vessel formation via ANGPT1/Tie2 pathway in rats with acute myocardial infarction. Biofabrication 19 34404035
2017 Germline Genetic Variants in TEK, ANGPT1, ANGPT2, MMP9, FGF2 and VEGFA Are Associated with Pathologic Complete Response to Bevacizumab in Breast Cancer Patients. PloS one 19 28045923
2015 COMP-Ang1 Potentiates EPC Treatment of Ischemic Brain Injury by Enhancing Angiogenesis Through Activating AKT-mTOR Pathway and Promoting Vascular Migration Through Activating Tie2-FAK Pathway. Experimental neurobiology 19 25792870
2015 Donor Heart Treatment With COMP-Ang1 Limits Ischemia-Reperfusion Injury and Rejection of Cardiac Allografts. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 19 25932532
2017 VEGF, ANGPT1, ANGPT2, and MMP-9 expression in the autologous hematopoietic stem cell transplantation and its impact on the time to engraftment. Annals of hematology 18 28956132
2015 The Angiopoietin-1 Variant COMP-Ang1 Enhances BMP2-Induced Bone Regeneration with Recruiting Pericytes in Critical Sized Calvarial Defects. PloS one 18 26465321
2013 Treatment with EGCG in NSCLC leads to decreasing interstitial fluid pressure and hypoxia to improve chemotherapy efficacy through rebalance of Ang-1 and Ang-2. Chinese journal of natural medicines 18 23725836
2018 [Aliskiren inhibits angiotensin II/angiotensin 1-7(Ang II/Ang1-7) signal pathway in rats with diabetic nephropathy]. Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology 16 30554582
2022 Knockdown of CDR1as Decreases Differentiation of Goat Skeletal Muscle Satellite Cells via Upregulating miR-27a-3p to Inhibit ANGPT1. Genes 15 35456469
2016 Subretinal AAV2.COMP-Ang1 suppresses choroidal neovascularization and vascular endothelial growth factor in a murine model of age-related macular degeneration. Experimental eye research 15 26775053
2016 COMP-Ang1 prevents periodontitic damages and enhances mandible bone growth in an experimental animal model. Bone 15 27612438
2016 Aflibercept and Ang1 supplementation improve neoadjuvant or adjuvant chemotherapy in a preclinical model of resectable breast cancer. Scientific reports 15 27841282
2015 A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041). Investigational new drugs 15 26686201
2013 COMP-Ang1 inhibits apoptosis as well as improves the attenuated osteogenic differentiation of mesenchymal stem cells induced by advanced glycation end products. Biochimica et biophysica acta 15 23850469
2012 Enhanced Angpt1/Tie2 signaling affects the differentiation and long-term repopulation ability of hematopoietic stem cells. Biochemical and biophysical research communications 15 23149415
2008 High-level expression and purification of a designed angiopoietin-1 chimeric protein, COMP-Ang1, produced in Chinese hamster ovary cells. The protein journal 15 18465215
2010 Real-time PCR study of Ang1, Ang2, Tie-2, VEGF, and KDR expression in human erectile tissue during aging. The journal of sexual medicine 14 21091880
2007 Blockade of airway inflammation and hyper-responsiveness by an angiopoietin-1 variant, COMP-Ang1. Experimental & molecular medicine 14 18160844
2023 Ang1/Tie2/VE-Cadherin Signaling Regulates DPSCs in Vascular Maturation. Journal of dental research 13 38058134
2021 COMP-Ang1: Therapeutic potential of an engineered Angiopoietin-1 variant. Vascular pharmacology 13 34583025
2018 Mesenchymal stem cells overexpressing Ang1 attenuates phosgene-induced acute lung injury in rats. Inhalation toxicology 13 30395743
2014 Molecular and cellular mechanisms of the inhibitory effects of ACE-2/ANG1-7/Mas axis on lung injury. Current topics in pharmacology 13 26146467
2013 COMP-Ang1 promotes chondrogenic and osteogenic differentiation of multipotent mesenchymal stem cells through the Ang1/Tie2 signaling pathway. Journal of orthopaedic research : official publication of the Orthopaedic Research Society 13 23893855
2012 The effects of Ang-1, IL-8 and TGF-β1 on the pathogenesis of COPD. Molecular medicine reports 13 22948395
2022 Intracameral Injection of AAV-DJ.COMP-ANG1 Reduces the IOP of Mice by Reshaping the Trabecular Outflow Pathway. Investigative ophthalmology & visual science 12 36520455
2021 Macrophages enhance lipopolysaccharide induced apoptosis via Ang1 and NF-κB pathways in human umbilical vein endothelial cells. Scientific reports 12 33536546
2016 Inhibition of angiopoietin-1 (ANGPT1) affects vascular integrity in ovarian hyperstimulation syndrome (OHSS). Reproduction, fertility, and development 12 25485810
2015 Transcriptional repression of ANGPT1 by histone H3K9 demethylase KDM3B. BMB reports 12 25413303
2013 Sequential, timely and controlled expression of hVEGF165 and Ang-1 effectively improves functional angiogenesis and cardiac function in vivo. Gene therapy 12 23514706
2022 Two-Stage Gene Therapy (VEGF, HGF and ANG1 Plasmids) as Adjunctive Therapy in the Treatment of Critical Lower Limb Ischemia in Diabetic Foot Syndrome. International journal of environmental research and public health 11 36232122
2012 Transgenic overexpression of keratinocyte-specific VEGF and Ang1 in combination promotes wound healing under nondiabetic but not diabetic conditions. International journal of clinical and experimental pathology 11 22295141
2024 Pericytes recruited by CCL28 promote vascular normalization after anti-angiogenesis therapy through RA/RXRA/ANGPT1 pathway in lung adenocarcinoma. Journal of experimental & clinical cancer research : CR 10 39075504
2020 New soluble angiopoietin analog of Hepta-ANG1 prevents pathological vascular leakage. Biotechnology and bioengineering 10 32970320
2019 COMP-Ang1 Stabilizes Hyperglycemic Disruption of Blood-Retinal Barrier Phenotype in Human Retinal Microvascular Endothelial Cells. Investigative ophthalmology & visual science 10 31415078
2016 COMP-Ang1 enhances DNA synthesis and cell cycle progression in human periodontal ligament cells via Tie2-mediated phosphorylation of PI3K/Akt and MAPKs. Molecular and cellular biochemistry 10 27107990
2020 Systemic AAV10.COMP-Ang1 rescues renal glomeruli and pancreatic islets in type 2 diabetic mice. BMJ open diabetes research & care 9 32792355
2014 Clonal Dominance With Retroviral Vector Insertions Near the ANGPT1 and ANGPT2 Genes in a Human Xenotransplant Mouse Model. Molecular therapy. Nucleic acids 9 25291142
2008 COMP-Ang1, angiopoietin-1 variant protects radiation-induced bone marrow damage in C57BL/6 mice. Journal of radiation research 9 18413981
2023 The expression analyses of GSK3B, VEGF, ANG1, and ANG2 in human brain microvascular endothelial cells treated with the synthetic cannabinoid XLR-11. Gene 8 37355149
2021 MiR-452 Regulates C2C12 Myoblast Proliferation and Differentiation via Targeting ANGPT1. Frontiers in genetics 8 33777108
2021 Local intramuscular administration of ANG1 and VEGF genes using plasmid vectors mobilizes CD34+ cells to peripheral tissues and promotes angiogenesis in an animal model. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 8 34649339
2019 Intravitreal AAV2.COMP-Ang1 Attenuates Deep Capillary Plexus Expansion in the Aged Diabetic Mouse Retina. Investigative ophthalmology & visual science 8 31185088
2013 Hypoxia reduces endothelial Ang1-induced Tie2 activity in a Tie1-dependent manner. Biochemical and biophysical research communications 8 23770419
2013 Forward mandibular positioning enhances the expression of Ang-1 and Ang-2 in rabbit condylar chondrocytes. Molecular medicine reports 8 23934380
2012 Plasma concentrations of Ang-1, Ang-2 and Tie-2 in gastric cancer. European cytokine network 8 22449617